Centers for Medicare & Medicaid Services Proposes Major Medicare

Note: This article is for educational and informational purposes only. Medicare rules can change faster than a teenager changes passwords, so beneficiaries, caregivers, providers, and plan sponsors should always review official CMS updates and plan documents before making coverage decisions.

The Centers for Medicare & Medicaid Services proposes major Medicare changes almost every year, but the latest cycle feels especially important because it touches the parts of Medicare that millions of Americans interact with most often: Medicare Advantage, Medicare Part D prescription drug coverage, quality ratings, enrollment rules, payment policy, prior authorization, and access to new medical technology. In plain English, CMS is trying to tune up a very large machine while it is already moving down the highway.

The headline may sound bureaucratic, but the impact is very real. A proposed Medicare rule can influence how easily a patient gets a drug approved, how much a Medicare Advantage plan receives in federal payments, how Star Ratings are calculated, how prescription drug costs are handled, and how quickly innovative medical devices become available to Medicare patients. That is not small potatoes. That is the whole Medicare casserole.

The most discussed Medicare proposal in this policy cycle is the Contract Year 2027 Medicare Advantage and Part D proposed rule. CMS released the proposal in late 2025, aiming to revise rules for Medicare Advantage, Medicare Part D, and Medicare cost plans. The proposal focused on improving quality, access, transparency, enrollment processes, drug coverage rules, and plan oversight. It was followed by a final rule in April 2026, with most policies applying to coverage beginning January 1, 2027.

What Is CMS Actually Proposing?

CMS oversees Medicare, Medicaid, the Children’s Health Insurance Program, and parts of the federal health insurance marketplace. When CMS proposes a Medicare rule, it is not simply floating a casual idea over coffee. It is beginning a formal rulemaking process. A proposed rule is published, the public can comment, CMS reviews feedback, and then the agency may issue a final rule.

For Medicare beneficiaries, these proposals matter because they shape what plans must do, how plans are paid, how plan quality is measured, and what protections are available when coverage becomes confusing. For insurers, hospitals, pharmacies, physicians, drug companies, medical device manufacturers, and advocates, these rules can reshape business strategies and patient-care workflows.

The current CMS Medicare policy package includes several major themes:

• Updating Medicare Advantage and Part D Star Ratings
• Codifying changes from the Inflation Reduction Act’s Part D redesign
• Changing how certain enrollment and plan processes work
• Adjusting Medicare Advantage payment and risk adjustment policies
• Increasing transparency around prior authorization
• Exploring faster Medicare coverage for breakthrough medical devices
• Strengthening rules around supplemental benefits and marketing practices

In short, CMS is trying to answer a difficult question: how can Medicare stay affordable, high-quality, understandable, and sustainable without making everyone involved need a nap and a legal dictionary?

Why Medicare Advantage Is at the Center of the Conversation

Medicare Advantage, also called Medicare Part C, allows private insurers to provide Medicare benefits under federal rules. These plans often include extra benefits, such as dental, vision, hearing, wellness services, transportation, or over-the-counter allowances. Many also include prescription drug coverage through Medicare Advantage Prescription Drug plans.

Because Medicare Advantage enrollment has grown significantly over time, CMS scrutiny has grown with it. The government pays Medicare Advantage plans to care for enrollees, and payment accuracy is a major concern. If plans are underpaid, they may reduce benefits or exit markets. If plans are overpaid, taxpayers foot the bill. Somewhere between those extremes is the policy sweet spot CMS keeps trying to find.

The 2027 Medicare Advantage and Part D payment policies finalized by CMS projected a net average increase of 2.48%, or more than $13 billion in additional Medicare Advantage payments for 2027. That increase was notably higher than the earlier advance notice estimate, which had suggested a much smaller increase. The change reflected CMS’s decision to continue using the 2024 Medicare Advantage risk adjustment model for 2027 while evaluating future updates.

Risk Adjustment: The Unsexy Policy That Moves Billions

Risk adjustment is one of those phrases that makes people stare into the middle distance, but it matters enormously. Medicare Advantage plans are paid more for members with higher expected health costs. That makes sense: a plan serving many people with diabetes, heart failure, cancer, or multiple chronic conditions needs more resources than a plan serving mostly healthier members.

The challenge is making sure diagnoses are accurate, connected to real care, and not simply used to inflate payments. CMS has been paying close attention to coding practices, chart reviews, and how diagnoses are documented. For 2027, CMS finalized a policy excluding diagnosis information from unlinked chart review records from risk score calculations, with limited exceptions. In everyday language, CMS is saying: if a diagnosis is not connected to an actual beneficiary encounter, do not expect it to count automatically.

This policy is important for taxpayers and plans alike. It pushes the system toward documentation that reflects real patient care, not just paperwork gymnastics. And let’s be honest: American health care already has enough paperwork to wallpaper the moon.

Star Ratings: CMS Wants Quality Scores to Mean More

Medicare Star Ratings help beneficiaries compare Medicare Advantage and Part D plans. Plans can receive from one to five stars, and higher-rated plans may receive quality bonus payments. These ratings influence consumer choice, plan reputation, and federal payment levels.

CMS proposed and later finalized significant updates to the Star Ratings system. The agency wanted to remove measures that were overly administrative or that no longer showed meaningful differences among plans. The final rule removed 11 measures CMS considered less useful or burdensome, while keeping the Diabetes Care – Eye Exam measure after stakeholders raised concerns.

The goal is to focus quality measurement on clinical outcomes, patient experience, access, and meaningful performance differences. In theory, this makes Star Ratings more useful for beneficiaries. In practice, it also changes the incentives for insurers. Plans will need to focus on what CMS chooses to measure, because in Medicare policy, what gets measured often gets managed, funded, celebrated, audited, or all four at once.

The Health Equity Debate

CMS also stepped back from implementing the Health Equity Index reward in the Star Ratings program. Supporters of health equity measures argue that plans should be rewarded for improving outcomes among underserved populations. Critics worry about complexity, scoring fairness, and unintended consequences. The final direction reflects CMS’s broader effort to simplify the ratings system, although the debate over health equity in Medicare is far from over.

For beneficiaries, the practical takeaway is simple: Star Ratings remain important, but they are not the whole story. A five-star plan may look shiny, but beneficiaries should still check doctors, prescriptions, pharmacies, prior authorization rules, out-of-pocket costs, and supplemental benefits before enrolling. A beautiful brochure cannot drive you to your cardiologist if your cardiologist is out of network.

Part D Prescription Drug Changes Are a Big Deal

Medicare Part D has gone through some of the biggest changes in its history because of the Inflation Reduction Act. The law redesigned the Part D benefit, eliminated the old coverage gap structure, created a hard annual out-of-pocket cap, and changed payment responsibilities among beneficiaries, plans, manufacturers, and the federal government.

For 2025, the annual Part D out-of-pocket threshold was set at $2,000. For 2026, it increased to $2,100. CMS’s 2027 rulemaking codifies many of these redesign policies into regulation, giving plans and stakeholders more certainty about how the new structure works.

This matters most for people who take expensive medications. Under the redesigned system, beneficiaries with high drug costs may have more predictable annual exposure. That does not mean every prescription becomes cheap. It does mean the old “surprise, your medicine now costs the price of a used kayak” experience is supposed to become less common.

Manufacturer Discount Program

The new Manufacturer Discount Program replaces the old Coverage Gap Discount Program. Under the redesigned Part D structure, drug manufacturers have specific discount responsibilities, and CMS has worked to clarify how those payments count in calculations such as gross covered prescription drug costs and medical loss ratio reporting.

These details may sound technical, but they affect how plans design formularies, manage premiums, and negotiate with manufacturers. The Part D redesign shifts financial responsibility around the system, and whenever billions of dollars shift seats, everyone checks the chair twice.

Drug Price Negotiation Adds Another Layer

Medicare drug price negotiation is also reshaping the prescription drug landscape. CMS has completed negotiation rounds for selected high-spending Part D drugs, with negotiated prices taking effect in stages. The first group of selected drugs includes medications used for diabetes, blood clots, heart failure, psoriasis, rheumatoid arthritis, Crohn’s disease, and certain cancers.

CMS has estimated major savings for Medicare and beneficiaries from negotiated prices. Policy analysts have also noted that later rounds could generate additional savings, although the final effect depends on utilization, plan behavior, manufacturer responses, and future drug selections.

For patients, the hope is straightforward: lower prescription costs and more predictable access. For the pharmaceutical industry, the concern is equally clear: reduced revenue on selected drugs and possible effects on investment decisions. For everyone else, the situation is a reminder that Medicare drug policy is basically chess, except every piece has lobbyists.

Prior Authorization: The Waiting Room Nobody Asked For

Prior authorization is one of the most frustrating parts of modern health care. It requires providers to get approval from a health plan before certain services, items, or drugs are covered. Supporters say it prevents unnecessary spending and inappropriate care. Critics say it delays treatment, burdens clinicians, and leaves patients stuck in administrative limbo.

CMS has proposed new interoperability and prior authorization standards for drugs. The proposal would require impacted payers to support electronic prior authorization, make faster decisions, improve transparency, and use updated health information technology standards. CMS is also proposing to incorporate drug-related coverage and documentation requirements into existing prior authorization application programming interfaces for drugs covered under a medical benefit beginning October 1, 2027.

The goal is to move prior authorization away from fax machines, phone tag, and paperwork scavenger hunts. Electronic systems should make it easier for providers to know what documentation is required, submit requests, receive decisions, and understand denials. If done well, this could reduce delays and administrative burden. If done poorly, it could simply create a shinier maze. Implementation will matter.

Faster Medicare Coverage for Breakthrough Devices

Another major Medicare development is CMS and FDA coordination to speed coverage for certain breakthrough medical devices. Under the RAPID pathway, eligible FDA-designated breakthrough devices could receive Medicare coverage much faster after FDA approval. Reports indicate the goal is to shorten timelines from a year or more to as little as 60 to 90 days for certain devices.

This is important because FDA approval does not automatically mean Medicare coverage. A device can be approved as safe and effective but still face delays before Medicare decides whether and how to pay for it. For patients with serious conditions, a year-long wait can feel like an eternity with a billing code attached.

Faster coverage could help patients access promising technologies sooner, while giving manufacturers clearer expectations. However, CMS must still balance speed with evidence, safety, clinical value, and taxpayer protection. Faster is good. Faster and responsible is better.

Supplemental Benefits and Marketing Rules

Medicare Advantage plans often compete through supplemental benefits, such as dental care, vision exams, hearing aids, transportation, meal support, home modifications, and debit-card-style allowances. These benefits can be valuable, especially for people with chronic conditions. But CMS has also worried about whether benefits are being marketed clearly, used appropriately, and tied to real health needs.

The 2027 Medicare rule includes guardrails around Special Supplemental Benefits for the Chronically Ill. CMS has clarified that benefits must meet eligibility standards and should not include products that are illegal under federal or applicable state law. The agency has also paid attention to debit card safeguards, marketing oversight, and third-party marketing organization practices.

This matters because Medicare advertising can be confusing. Many beneficiaries have seen commercials promising extra benefits with the enthusiasm of a game show host. CMS wants marketing to be clearer, less misleading, and more useful. Beneficiaries deserve plain information, not confetti cannons of fine print.

Special Enrollment Periods and Provider Networks

One proposal that drew attention involved special enrollment rights when a provider or facility leaves a Medicare Advantage network. CMS considered making it easier for affected enrollees to change plans when their provider relationship is disrupted. Hospitals and advocates paid close attention because provider terminations can be deeply disruptive for patients, especially those receiving ongoing care.

CMS ultimately did not finalize the proposed change in the 2027 final rule. Still, the issue remains important. Network stability is one of the biggest practical differences between Original Medicare and Medicare Advantage. A plan may have great premiums and benefits, but if a trusted oncologist, cardiologist, primary care doctor, or hospital leaves the network, the beneficiary’s real-world experience can change overnight.

What These Medicare Changes Mean for Beneficiaries

For people enrolled in Medicare, the main message is not panic. It is preparation. CMS proposals and final rules do not always change coverage immediately, and many policies apply to future plan years. But beneficiaries should pay attention during Medicare Open Enrollment, which runs from October 15 through December 7 each year.

Here are practical steps beneficiaries can take:

• Review the Annual Notice of Change from your plan.
• Check whether your doctors and hospitals remain in network.
• Confirm that your prescriptions are still covered and compare tiers.
• Look beyond the premium and estimate total yearly costs.
• Review Star Ratings, but do not rely on them alone.
• Ask whether services require prior authorization.
• Compare Medicare Advantage with Original Medicare and Medigap options where available.

A Medicare plan is not just an insurance card. It is a set of rules about doctors, drugs, referrals, networks, pharmacies, approvals, appeals, and costs. Choosing one based only on a zero-dollar premium is like buying a car because the cupholder is nice.

What These Changes Mean for Providers and Plans

For providers, CMS’s direction suggests more pressure for cleaner documentation, electronic prior authorization workflows, quality reporting, and coordination with Medicare Advantage plans. Hospitals and physician groups will need to watch network rules, utilization management standards, claims processing, and plan payment behavior.

For insurers, the message is mixed. Payment increases for 2027 offer relief, but CMS continues to focus on risk adjustment accuracy, quality measurement, supplemental benefit integrity, and marketing practices. Plans may need to rethink benefit design, coding operations, Star Ratings strategy, formulary placement, and provider relationships.

For drug companies and device manufacturers, Medicare policy is becoming both more opportunity-rich and more demanding. Drug price negotiation and Part D redesign create pressure on pharmaceutical economics. Faster device coverage pathways may create opportunities for medical technology companies, but they also raise the bar for evidence and value.

Analysis: CMS Is Trying to Simplify a Complicated Program

The biggest theme running through the CMS Medicare proposals is simplification. CMS wants Star Ratings that focus on meaningful differences. It wants prior authorization to move electronically. It wants Part D redesign rules codified. It wants Medicare Advantage payment to better reflect true risk. It wants beneficiaries to compare plans more easily.

But simplification in Medicare is hard because Medicare is not one program in practice. It is a layered system of public benefits, private plans, pharmacy rules, risk models, provider networks, drug pricing policies, quality measures, and political expectations. Every adjustment helps one group, worries another, and sends consultants sprinting toward their PowerPoint decks.

The challenge for CMS is to protect beneficiaries while maintaining plan participation and taxpayer sustainability. If rules are too strict, plans may reduce benefits or leave markets. If rules are too loose, beneficiaries may face confusing marketing, excessive denials, unstable networks, or inflated taxpayer costs. The best policy path is rarely dramatic. It is usually technical, incremental, and deeply argued over by people who know what “subregulatory guidance” means.

Experiences Related to CMS Proposes Major Medicare

For many families, Medicare policy becomes personal long before it becomes understandable. A son helping his mother compare Medicare Advantage plans may not care about the exact wording of a CMS proposed rule. He cares whether her heart medication is covered, whether her cardiologist is still in network, and whether the plan will approve the test her doctor ordered. That is where CMS rulemaking touches the kitchen table.

Consider a retiree named Linda, age 72, who takes three brand-name medications and sees two specialists. During open enrollment, she sees a Medicare Advantage plan with a low premium and generous dental benefits. It looks fantastic. Then she learns one of her drugs moved to a higher tier, her preferred pharmacy is no longer preferred, and her specialist requires prior authorization for a treatment that used to be routine. Suddenly, the “best” plan is not the best plan for her. CMS proposals around Part D redesign, Star Ratings, prior authorization transparency, and plan comparisons are meant to make Linda’s decision easier and less risky.

Or picture a primary care clinic trying to serve hundreds of Medicare Advantage patients. The physicians want to spend time on blood pressure, diabetes, fall risk, depression screening, and medication adherence. Instead, staff members often spend hours chasing approvals, resubmitting records, calling plans, and explaining delays to patients. If CMS’s electronic prior authorization standards work as intended, that clinic could spend less time wrestling with administrative octopus arms and more time practicing medicine.

There is also the experience of caregivers. Adult children often become unofficial Medicare project managers for parents. They compare plan documents, call customer service, check drug formularies, and try to decode phrases like “step therapy,” “maximum out-of-pocket,” “prior authorization,” and “preferred cost-sharing pharmacy.” A clearer Medicare system would not eliminate every headache, but it could reduce the number of times caregivers say, “Why is this so complicated?” into the phone.

For plan sponsors, the experience is different but just as intense. A Medicare Advantage organization preparing bids for 2027 has to model payment rates, risk adjustment rules, Star Ratings changes, utilization trends, supplemental benefit costs, provider contracts, marketing requirements, and Part D liabilities. One CMS proposal can alter the economics of an entire product line. A final rule can determine whether a plan expands, shrinks, changes benefits, or exits a county.

Hospitals and specialists also feel the ripple effects. When Medicare Advantage plans adjust networks or authorization rules, providers may see changes in referrals, claim denials, cash flow, and patient continuity. A hospital does not need to be an insurer to feel Medicare Advantage policy in its emergency department, billing office, and care management team.

The human lesson is simple: Medicare policy is not abstract. It shows up as a patient waiting for approval, a pharmacist explaining a copay, a caregiver comparing plans at midnight, a physician documenting a diagnosis, an insurer redesigning benefits, and a regulator trying to keep the whole system from wobbling. CMS’s proposed Medicare changes matter because behind every acronym is a person who just wants care to be affordable, accessible, and understandable.

Conclusion

The Centers for Medicare & Medicaid Services proposes major Medicare changes to keep pace with a health system that is expensive, complicated, and constantly evolving. The CY 2027 Medicare Advantage and Part D rulemaking cycle shows CMS trying to sharpen quality measurement, stabilize plan payments, codify prescription drug reforms, improve transparency, modernize prior authorization, and strengthen oversight of benefits and marketing.

For beneficiaries, the best response is to stay alert and compare plans carefully. For providers, the priority is operational readiness and documentation accuracy. For insurers, the message is to prepare for continued scrutiny around value, quality, coding, and beneficiary experience. For policymakers, the work is far from finished.

Medicare may never be simple enough to explain on a napkin, but good policy can make it less confusing, more accountable, and more humane. That is the real promise behind CMS’s major Medicare proposals: not just better rules, but a better experience for the people who depend on Medicare every day.